Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Asthma and COPD Drugs Market size is likely to expand from USD 40.5 billion in 2024 to USD 108.83 billion by 2037, demonstrating a CAGR of around 7.9% throughout the forecast period, from 2025 to 2037. Currently in 2025, the industry revenue of asthma and COPD drugs is estimated at USD 42.74 billion.
The industry includes a variety of drugs, including bronchodilators, corticosteroids, combination therapies, and monoclonal antibodies. Furthermore, there have been surging investments in drugs, and therapy by competitors for the cure of diseases in order to have a competitive advantage.
Asthma and COPD Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Rising prevalence of Asthma and COPD – The growth of the asthma and COPD drugs market is mainly driven by the increasing prevalence of COPD and asthma. For example, according to data stated by the World Health Organization (WHO) in 2019, asthma affected about 262 million population. Moreover, according to the fact stated by American Lung Organization in 2018, 99 million people in the United States have chronic bronchitis.
- Development in Respiratory Diseases Therapeutics – There has been increasing in the launch of new products for the medication of chronic obstructive pulmonary diseases. For example, AstraZenca, obtained European approval for "Trixeo Aerosphere" for the maintenance cure of COPD.
- Increasing healthcare expenditure – Healthcare expenditure is on the rise globally, driven by factors such as population growth, aging, and the increasing burden of chronic diseases.
Challenges
- Patent Expirations – Many of the blockbuster drugs used to treat respiratory diseases are coming off patent, which is leading to increased competition from generic drugs. This is likely to reduce the revenue of branded drugs and increase pressure on drug manufacturers to develop new and innovative drugs.
- High cost of drugs
- Adverse effects of drugs
Asthma and COPD Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.9% |
|
Base Year Market Size (2024) |
USD 40.5 billion |
|
Forecast Year Market Size (2037) |
USD 108.83 billion |
|
Regional Scope |
|
Asthma and COPD Drugs Segmentation
End User (Asthma Patients, COPD Patients)
The COPD patients’ segment in the asthma and COPD drugs market is expected to witness around 60% growth rate through 2037. The growth of the segment can be accredited to the increasing prevalence of smoking.
Smoking is a major cause of COPD. While smoking rates have been declining in many parts of the world, there are still significant numbers of smokers, particularly in low- and middle-income countries. This is estimated to contribute to the increasing prevalence of COPD and drive demand for COPD drugs.
Distribution Channel (General Pharmacies, Online Retailers, Hospital Pharmacies)
The hospital pharmacies segment is estimated to gain the largest market share in the year 2037. Respiratory diseases such as asthma and COPD can require hospitalization, particularly in severe cases. The increasing prevalence of these conditions is likely to lead to an increase in hospitalizations.
According to a study of 2020, hospitalizations for asthma increased during the COVID-19 pandemic in several countries, across the globe. The study found that hospitalizations for asthma increased by 30-70% in these countries during the pandemic.
Our in-depth analysis of the global market includes the following segments:
|
Distribution Channel |
|
|
End User |
|
|
Route of Administration |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAsthma and COPD Drugs Industry - Regional Synopsis
North American Market Forecast
The North America region in asthma and COPD drugs market is estimated to account for significant revenue share by 2037. The growing healthcare infrastructure in the North American region is able to provide the required treatment to the patients.
In addition, the governments and private insurance companies generally provide favorable reimbursement policies for drugs dispensed through pharmacies and hospitals.
APAC Market Statistics
The Asia Pacific asthma and COPD drugs market is poised to register substantial growth rate during the forecast period. The aging population in the Asia Pacific region is growing rapidly, which is expected to lead to an increase in the number of people with respiratory diseases.
Several governments are taking initiatives to improve healthcare access and outcomes, including for respiratory diseases. For instance, the Chinese government launched the "Healthy China 2030" initiative, which aims to reduce the burden of chronic diseases.
Companies dominating the Asthma and COPD Drugs Landscape
- GlaxoSmithKline plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- CHIESI Farmaceutici S.p.A.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Abbott
In the News
- Dignity Health, and Propeller Health announced that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system, which is fully implemented in seven communities served by Dignity Health physicians and clinics in Arizona and California.
- True Corporation along with partners, Easy Asthma & COPD Clinics (EACC), a network of respiratory disease treatment clinics, and GlaxoSmithKline Thailand (GSK), a researcher and developer of innovative drugs and vaccines, launched “Telehealth Together” project to take care of patients suffering from respiratory diseases using True's health intelligent healthcare platform for telehealth services.
Author Credits: Radhika Pawar
- Report ID: 4116
- Published Date: Mar 21, 2025
- Report Format: PDF, PPT
